A potential role for daptomycin in enterococcal infections: what is the evidence?
about
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococciIn vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pHGenetic basis for daptomycin resistance in enterococci.Clinical experience with daptomycin in Europe: the first 2.5 years.Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series.Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.Genetic basis for in vivo daptomycin resistance in enterococci.Mechanisms of antibiotic resistance in enterococci.Multiple roles for Enterococcus faecalis glycosyltransferases in biofilm-associated antibiotic resistance, cell envelope integrity, and conjugative transfer.Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs PatientsGlycopeptide resistance in gram-positive cocci: a review.Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.Intrinsic and acquired resistance mechanisms in enterococcus.Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapyA current perspective on daptomycin for the clinical microbiologist.Surveillance and management of multidrug-resistant microorganisms.Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?Current use of daptomycin in cardiac surgery and postoperative intensive care.The cell wall architecture of Enterococcus faecium: from resistance to pathogenesis.Antibiotic resistance in Enterococcus faecium clinical isolates.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Lipopeptide Laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis.Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.Characterization of daptomycin non-susceptible Enterococcus faecium producing urinary tract infection in a renal transplant recipient.Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay usiMethicillin-Resistant Staphylococcus aureus Prostatic Abscess in a Liver Transplant Recipient.Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004-2009).Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009.A rationale for combination ampicillin and daptomycin in renal transplant patients with enterococcal infective endocarditis
P2860
Q26851754-751E287A-A476-4421-A894-14DBDD061C5AQ28488311-A875AE6E-54C3-455A-8F37-A39C0432BD76Q33876255-AEF12333-030E-4226-ACB6-5A36AD17619CQ34681219-B36CD139-A853-4C9A-9188-4AF155C7214AQ34835269-C8218EBE-18D8-4A93-A34B-03A2DCC18F9FQ34871254-6B91A1A0-E224-4C8E-9976-1EA14C79AA83Q35270357-441DA793-61F5-4005-AE77-C4A77DD467FFQ35499202-D4A89E8D-B9F1-4942-AADE-E153DA227134Q35610646-20DB7EFD-BFAE-49EF-B3A8-62F7B5D6AF5CQ35616215-160A9C93-2C33-4333-A524-B382E5C599E5Q35999714-617C423F-A361-4650-989E-BEF578E99913Q36072225-1BD56F10-6D00-47BA-93F5-E0DAA535D2C7Q36171704-78ED6C32-ABC7-42CD-A7BC-9C7702DE090EQ36362547-B4B577F3-5E53-455E-BA66-2F39CAEFA3D5Q36505376-4D3FF16C-25D1-4B98-90D1-A7225698C366Q37263289-98054B58-1EF1-4A73-A0DE-A0B301C79082Q37912231-4E4FB2B5-ECF6-4717-A34A-73D858BF70D8Q38064807-64E0CBF7-93D3-4F5D-8F39-0855BDD1630FQ38086339-8557E78D-DA6E-4C1B-967F-244B3BEA19C8Q38125495-C9AE0B7D-D49C-4719-8D91-43B48E63A9F9Q38176042-FF2391B0-7B4A-4488-BF94-69B7DCF49061Q38263421-458D719F-F2B6-4C66-8676-FA2CC3AA3CE9Q39773341-B96F1F1C-9AF0-4A29-BC13-D758E18B46CBQ40676263-7FB613B7-D1EC-40DF-B05C-FB9C9517610BQ41096202-070B4E28-F7BA-4F00-B71C-CCD3261E325AQ42003344-D2E56435-297C-4FB3-8497-98C99141D414Q42972012-4EBF1F05-88DA-49AA-9B66-0F1D2006106DQ46556054-C937A285-6485-4B40-932F-6FB650346023Q47828777-8FEA08FB-7026-4B65-BBF7-8F4816207BD1Q58121281-29543D6D-2A35-46BE-8CD0-2635B8ED4EFA
P2860
A potential role for daptomycin in enterococcal infections: what is the evidence?
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A potential role for daptomycin in enterococcal infections: what is the evidence?
@ast
A potential role for daptomycin in enterococcal infections: what is the evidence?
@en
type
label
A potential role for daptomycin in enterococcal infections: what is the evidence?
@ast
A potential role for daptomycin in enterococcal infections: what is the evidence?
@en
prefLabel
A potential role for daptomycin in enterococcal infections: what is the evidence?
@ast
A potential role for daptomycin in enterococcal infections: what is the evidence?
@en
P2093
P2860
P921
P356
P1476
A potential role for daptomycin in enterococcal infections: what is the evidence?
@en
P2093
Alan P Johnson
Patricia Ruiz-Garbajosa
Rafael Cantón
Ricardo L Chaves
P2860
P304
P356
10.1093/JAC/DKQ087
P407
P577
2010-04-02T00:00:00Z
2010-06-01T00:00:00Z